{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-154190","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.880589+00:00","generated_at":"2026-06-14T14:23:24.738281+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Agios director John Maraganore resigns; Catherine Owen elected to board","bullets":["John Maraganore resigned from board effective May 24, 2023, after nearly 12 years.","Kaye Foster appointed lead independent director; Cynthia Smith becomes Compensation & People Committee chair.","Catherine Owen elected as class II director effective June 13, 2023; joins Compensation & People Committee.","Owen receives annual cash: $50,000 as director plus $7,500 for committee service.","Owen granted initial equity: nonstatutory option with $472,500 Black-Scholes value and RSUs valued at $157,500."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-154190","json":"https://secwatch.observer/filing/0001193125-23-154190.json","markdown":"https://secwatch.observer/filing/0001193125-23-154190.md","text":"https://secwatch.observer/filing/0001193125-23-154190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/d509829d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:23:24.738281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53d55e9cfa","claim":"John Maraganore resigned as Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"John Maraganore, Ph.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective May 24, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"606f11cb01","claim":"Catherine Owen was elected as Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"elected Catherine Owen as a director, effective as of June 13, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ac700a4e44","claim":"Kaye Foster was appointed as Lead Independent Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"appointed director Kaye Foster to serve as the Board’s lead independent director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523154190/0001193125-23-154190-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}